

Luisa Guidi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8770293/publications.pdf>

Version: 2024-02-01

108
papers

3,388
citations

117453

34
h-index

155451

55
g-index

109
all docs

109
docs citations

109
times ranked

4470
citing authors

#	ARTICLE	IF	CITATIONS
1	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 30-35.	2.4	316
2	The Effect of Zinc and Vitamin A Supplementation on Immune Response in an Older Population. <i>Journal of the American Geriatrics Society</i> , 1998, 46, 19-26.	1.3	140
3	The PROSIT-BIO Cohort. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 233-243.	0.9	116
4	Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 769-779.	0.6	114
5	Increased carotid intima-media thickness in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 839-846.	1.9	97
6	Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 880-888.	1.9	94
7	Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti-TNF agents: Effects of combined therapy with immunosuppressants. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 301-307.	0.6	86
8	Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: An open-label pilot study. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e623-e629.	0.6	85
9	Management of perianal fistulas in Crohn's disease: An up-to-date review. <i>World Journal of Gastroenterology</i> , 2015, 21, 1394.	1.4	82
10	Anti-TNF therapy for ulcerative colitis: current status and prospects for the future. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 223-233.	1.3	78
11	Ileal Crohn Disease: Mural Microvascularity Quantified with Contrast-enhanced US Correlates with Disease Activity. <i>Radiology</i> , 2012, 262, 680-688.	3.6	74
12	Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. <i>European Journal of Immunology</i> , 2011, 41, 1120-1131.	1.6	72
13	Adalimumab in active ulcerative colitis: A real-life observational study. <i>Digestive and Liver Disease</i> , 2013, 45, 738-743.	0.4	72
14	Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor agents. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 113-119.	0.6	68
15	Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. <i>International Journal of Colorectal Disease</i> , 2011, 26, 1435-1444.	1.0	66
16	Infliximab in Steroid-dependent Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1065-1072.	0.9	66
17	Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. <i>Digestive and Liver Disease</i> , 2014, 46, 974-979.	0.4	64
18	Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF) on the Liver. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2199.	1.8	62

#	ARTICLE	IF	CITATIONS
19	Linking estrogen receptor $\hat{1}^2$ expression with inflammatory bowel disease activity. <i>Oncotarget</i> , 2015, 6, 40443-40451.	0.8	58
20	Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1368-1374.	0.9	55
21	Forkhead box protein 3 (FOXP3) mutations lead to increased TH17 cell numbers and regulatory T-cell instability. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1376-1379.e1.	1.5	54
22	Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 852-858.	0.6	54
23	Multidetector CT enteroclysis versus barium enteroclysis with methylcellulose in patients with suspected small bowel disease. <i>European Radiology</i> , 2006, 16, 1527-1536.	2.3	52
24	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 568-579.	0.9	51
25	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1079-1088.	0.6	50
26	Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn's disease: CT findings and correlation with endoscopy. <i>European Radiology</i> , 2009, 19, 2432-2440.	2.3	45
27	Internet use among inflammatory bowel disease patients: an Italian multicenter survey. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1036-1041.	0.8	42
28	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.4	42
29	Impairment of lymphocyte activities in depressed aged subjects. <i>Mechanisms of Ageing and Development</i> , 1991, 60, 13-24.	2.2	40
30	Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre. <i>United European Gastroenterology Journal</i> , 2020, 8, 775-781.	1.6	40
31	Myasthenia gravis, thymectomy, and antiacetylcholine receptor antibody. <i>Journal of Neurology</i> , 1980, 224, 9-15.	1.8	38
32	Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. <i>Techniques in Coloproctology</i> , 2008, 12, 111-117.	0.8	38
33	Citation classics in periodontology: a controlled study. <i>Journal of Clinical Periodontology</i> , 2007, 34, 349-358.	2.3	37
34	Use of Infliximab in Particular Clinical Settings: Management Based on Current Evidence. <i>American Journal of Gastroenterology</i> , 2009, 104, 1575-1586.	0.2	37
35	Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 335-339.	0.6	37
36	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.4	36

#	ARTICLE	IF	CITATIONS
37	Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110066.	1.4	34
38	Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Caseâ€“Control IG-IBD Study. Inflammatory Bowel Diseases, 2019, 26, 450-459.	0.9	33
39	Neuropeptide Y Plasma Levels and Immunological Changes during Academic Stress. Neuropsychobiology, 1999, 40, 188-195.	0.9	32
40	FOXP3 ⁺ Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF Agents. BioMed Research International, 2013, 2013, 1-10.	0.9	31
41	Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. United European Gastroenterology Journal, 2019, 7, 1189-1197.	1.6	31
42	Effect of age on DNA binding of the ku protein in irradiated human peripheral blood mononuclear cells (PBMC). Experimental Gerontology, 1999, 34, 645-658.	1.2	30
43	Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. Journal of Crohn's and Colitis, 2016, 10, 913-924.	0.6	30
44	The efficacy of chemotherapy with mebendazole in human cystic echinococcosis: long-term follow-up of 52 patients. Annals of Tropical Medicine and Parasitology, 1992, 86, 249-256.	1.6	29
45	Update on the management of inflammatory bowel disease: specific role of adalimumab. Clinical and Experimental Gastroenterology, 2011, 4, 163.	1.0	29
46	Psychoneuroimmunology and Aging. Gerontology, 1998, 44, 247-261.	1.4	26
47	Increased Levels of NF-Î²B Inhibitors (Î²Î± and Î²Î³) in the Intestinal Mucosa of Crohn's Disease Patients during Infliximab Treatment. International Journal of Immunopathology and Pharmacology, 2005, 18, 155-164.	1.0	26
48	CT findings and clinical activity in Crohn's disease. Clinical Imaging, 2009, 33, 123-129.	0.8	26
49	Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IGâ€“IBD LIVE study. Alimentary Pharmacology and Therapeutics, 2022, 56, 95-109.	1.9	25
50	The Italian registry of therapeutic apheresis: Granulocyteâ€“monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. Journal of Clinical Apheresis, 2011, 26, 332-337.	0.7	23
51	DNA damage recognition and repair capacities in human naÃ“ve and memory T cells from peripheral blood of young and elderly subjects. Mechanisms of Ageing and Development, 2003, 124, 517-524.	2.2	22
52	Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2021, 10, 853.	1.0	22
53	Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use. Inflammatory Bowel Diseases, 2008, 14, 1168-1170.	0.9	21
54	Ileal Crohn's disease: CEUS determination of activity. Abdominal Imaging, 2012, 37, 359-368.	2.0	21

#	ARTICLE	IF	CITATIONS
55	A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: Infliximab and surgery. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 421-426.	0.6	18
56	Serum triiodothyronine to thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 273-280.	1.9	18
57	Changes in the amount and level of phosphorylation of p56lck in PBL from aging humans. <i>Mechanisms of Ageing and Development</i> , 1998, 102, 177-186.	2.2	17
58	Cell proliferation and ku protein expression in ageing humans. <i>Mechanisms of Ageing and Development</i> , 1998, 100, 197-208.	2.2	15
59	Role of immune responsiveness and DNA repair capacity genes in ageing. <i>Ageing Research Reviews</i> , 2004, 3, 143-151.	5.0	15
60	Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. <i>RMD Open</i> , 2018, 4, e000667.	1.8	15
61	TRPM7 is overexpressed in human IBD-related and sporadic colorectal cancer and correlates with tumor grade. <i>Digestive and Liver Disease</i> , 2020, 52, 1188-1194.	0.4	15
62	Plasma Thrombin-Antithrombin Complexes, Latent Coagulation Disorders and Metastatic Spread in Lung Cancer: A Longitudinal Study. <i>Oncology</i> , 1996, 53, 455-460.	0.9	14
63	Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2004, 36, 528-532.	0.4	14
64	Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 751-759.	1.3	14
65	Role of DNA-dependent protein kinase in recognition of radiation-induced DNA damage in human peripheral blood mononuclear cells. <i>International Immunology</i> , 2001, 13, 791-797.	1.8	13
66	Interleukin-6 release in the hepatic blood outflow during normothermic liver ischaemia in humans. <i>Digestive and Liver Disease</i> , 2003, 35, 409-415.	0.4	13
67	Therapeutic drug monitoring of anti-TNF agents in inflammatory bowel diseases. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1107-1117.	1.4	13
68	Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2013, 22, 21-5.	0.5	13
69	Immune parameters in a population of institutionalized elderly subjects: influence of depressive disorders and endocrinological correlations. <i>Mechanisms of Ageing and Development</i> , 1991, 60, 1-12.	2.2	12
70	Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach. <i>Italian Journal of Pediatrics</i> , 2021, 47, 18.	1.0	12
71	AID in aging and autoimmune diseases. <i>Autoimmunity</i> , 2013, 46, 168-175.	1.2	11
72	Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab. <i>Drug Design, Development and Therapy</i> , 2013, 7, 289.	2.0	8

#	ARTICLE	IF	CITATIONS
73	Latent Coagulation Disorders Evaluated by the Assay of Plasma Thrombin-Antithrombin III Complexes in a Large Series of "Solid Tumours". <i>Oncology</i> , 1992, 49, 426-430.	0.9	7
74	The DNA repair protein ku is involved in gp130-mediated signal transduction events in PBMC from young but not from elderly subjects. <i>Experimental Gerontology</i> , 2002, 37, 321-328.	1.2	7
75	Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study. <i>Digestive and Liver Disease</i> , 2017, 49, 997-1002.	0.4	7
76	Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	0.7	7
77	Assay, Isolation and Characterization of Circulating Immune Complexes from Serum of Gastrointestinal Cancer, Stage III and IV Melanoma and Chronic Inflammatory Bowel Disease Patients. <i>Oncology</i> , 1993, 50, 27-34.	0.9	6
78	What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 387.	0.6	6
79	Psychological Status of Institutionalized Aged: Influences on Immune Parameters and Endocrinological Correlates. <i>International Journal of Neuroscience</i> , 1990, 51, 279-281.	0.8	5
80	Modulation of X-ray-induced damage recognition and repair in ageing human peripheral blood mononuclear cells by an interleukin-6-type cytokine. <i>Mechanisms of Ageing and Development</i> , 2001, 121, 5-19.	2.2	5
81	Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. <i>Current Medical Research and Opinion</i> , 2020, 36, 7-8.	0.9	5
82	Treatment of Crohn's disease with colony-stimulating factors: An overview. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 927-934.	0.9	5
83	Incident Colorectal Cancer in Inflammatory Bowel Disease. <i>Cancers</i> , 2022, 14, 721.	1.7	5
84	A Case of Hereditary Hemorrhagic Telangiectasia Associated With Crohn's Disease Successfully Treated With Infliximab. <i>American Journal of Gastroenterology</i> , 2010, 105, 1904.	0.2	4
85	Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 65, 280-290.	2.2	4
86	Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis. <i>Drug, Healthcare and Patient Safety</i> , 2016, 8, 1.	1.0	3
87	Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 97-104.	1.4	3
88	Watery stools and metabolic acidosis. <i>Internal and Emergency Medicine</i> , 2017, 12, 487-492.	1.0	2
89	Psychological status, life and social conditions: A study in a population of institutionalized elderly people. <i>International Journal of Geriatric Psychiatry</i> , 1993, 8, 419-426.	1.3	1
90	From initial case report to randomized clinical trial through 20 years of research in periodontal therapy. <i>Journal of Clinical Periodontology</i> , 2009, 36, 39-43.	2.3	1

#	ARTICLE	IF	CITATIONS
91	342 Retreatment With Infliximab in Inflammatory Bowel Disease: Tolerability and Effectiveness of Different Re-Induction Regimens. <i>Gastroenterology</i> , 2014, 146, S-78-S-79.	0.6	1
92	Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. <i>Digestive and Liver Disease</i> , 2014, 46, 290-291.	0.4	1
93	Dual Targeted Therapy in Patient With Extensive Crohn's Disease: Different Response at Distinct Location. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e93-e94.	0.9	1
94	Lymphocyte Proliferative Response to <i>Helicobacter pylori</i> CagA Protein in Patients with Duodenal Ulcer or Gastritis. <i>Journal of Clinical Gastroenterology</i> , 1996, 23, 81-82.	1.1	1
95	Mucosal healing in ulcerative colitis: surveillance or colectomy?. <i>Annals of Gastroenterology</i> , 2013, 26, 355.	0.4	1
96	Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 313-320.	1.4	1
97	Soluble immunosuppressor factors in human cancer. <i>Clinical Immunology Newsletter</i> , 1988, 9, 124-127.	0.1	0
98	Characteristics of Gastric-Vein Lymphocytes with Regard to the Immune Response to <i>Helicobacter pylori</i> . <i>Scandinavian Journal of Gastroenterology</i> , 1999, 34, 757-764.	0.6	0
99	Small bowel Gd-enhanced MRI at 0.5T using enteroclysis with a superparamagnetic oral agent in Crohn's disease. <i>Gastroenterology</i> , 2000, 118, A1338.	0.6	0
100	Role of DNA-dependent protein kinase (DNA-PK), a protein with multiple intracellular functions, in cells of the ageing immune system. <i>Advances in Cell Aging and Gerontology</i> , 2002, , 217-230.	0.1	0
101	Duodenoscopy & Capsule Endoscopy: A New Method to "Staging" Coeliac Disease. <i>Gastrointestinal Endoscopy</i> , 2005, 61, AB162.	0.5	0
102	W1049 Quantification of Microvascular Activation in Ileal Crohn's Disease By Software Elaboration Data Applied to CEUS: Correlation with Biological Activity Indexes. <i>Gastroenterology</i> , 2009, 136, A-643.	0.6	0
103	In Vivo and In Vitro Immune Response to Pandemic Influenza 2009 H1N1 Vaccine in Inflammatory Bowel Disease Patients on Anti TNF-Alpha Treatment. <i>Gastroenterology</i> , 2011, 140, S-274.	0.6	0
104	Response to Influenza Vaccine a/H1N1 2009 in Patients With Inflammatory Bowel Disease on Anti TNF-Alpha Therapy. <i>Gastroenterology</i> , 2011, 140, S-274.	0.6	0
105	P.1.218: INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS ON ANTI TNF-ALPHA TREATMENT: RESPONSE TO THE INFLUENZA A/H1N1 VACCINE IN VIVO AND IN VITRO. <i>Digestive and Liver Disease</i> , 2011, 43, S220.	0.4	0
106	Infliximab: A Review of Its Use in the Treatment of Inflammatory Bowel Disease. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S1978.	0.4	0
107	TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine. <i>EBioMedicine</i> , 2019, 41, 40-41.	2.7	0
108	Small bowel diseases. <i>Rays</i> , 2002, 27, 3-10.	0.2	0